MALT1 and lymphoma: Potential treatment of lymphomas with a MALT1 inhibitor has been contemplated based on numerous studies showing that MALT1 protease function is a key driver for proliferation of e.g., ABC-DLBCL lymphomas (10, 11) and MALT1 protease inhibitors are now entering clinical trials for these indications (43).